Support Measures Herald New Drug Rush In China?
This article was originally published in PharmAsia News
Domestic developers of original drugs in China are beginning to gain clinical trial approvals (CTAs) in record times, especially for therapies to treat prevalent serious diseases such as cancers and hepatitis, helped by alliances with academia, the government push for innovation, and major CRO WuXi.
You may also be interested in...
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
China releases technical requirements for foreign drug makers to register their chemical drugs in the country, and issues patent linkage details, which a legal expert says needs to be closely examined.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.